Understanding The Role of LDLRAD4 in Lipid Metabolism and Disease

Target Name: LDLRAD4

NCBI ID: G753

LDLRAD4

Understanding The Role of LDLRAD4 in Lipid Metabolism and Disease

Low density lipoprotein receptor class A domain containing 4 (LDLRAD4) is a protein that is expressed in various tissues throughout the body, including liver, muscle, and fat cells. It is a type of transmembrane protein that is characterized by the presence of a long N-terminus that is involved in several different signaling pathways.

One of the most significant functions of LDLRAD4 is its role in the regulation of lipid metabolism. It is a receptor for low density lipoprotein (LDL), which is a primary form of cholesterol in the blood. LDL is known to be a risk factor for the development of cardiovascular disease, and research has suggested that LDLRAD4 may play a role in the regulation of cholesterol levels and the development of atherosclerosis.

LDLRAD4 is also involved in the regulation of inflammation and immune responses. It has been shown to be a receptor for several different types of cytokines, which are proteins that are released by the immune system in response to the presence of foreign substances in the body. This suggests that LDLRAD4 may play a role in the regulation of immune responses and the development of autoimmune diseases.

LDLRAD4 is also involved in the regulation of cell signaling pathways. It has been shown to play a role in several different signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. These pathways are involved in the regulation of cell growth, differentiation, and survival, and research has suggested that LDLRAD4 may be involved in the regulation of these processes in a variety of tissues.

LDLRAD4 is also a potential drug target in the development of certain diseases. For example, research has suggested that LDLRAD4 may be a potential target for the development of atherosclerosis, a condition in which plaque builds up in the arteries and can cause a heart attack or stroke. Additionally, LDLRAD4 has been shown to be involved in the regulation of lipid metabolism, which is a risk factor for the development of metabolic diseases such as diabetes and obesity.

In conclusion, LDLRAD4 is a protein that is expressed in various tissues throughout the body that is involved in several different signaling pathways. It is a potential drug target and biomarker for several different diseases, including atherosclerosis and metabolic diseases. Further research is needed to fully understand the role of LDLRAD4 in these processes and to develop effective treatments.

Protein Name: Low Density Lipoprotein Receptor Class A Domain Containing 4

Functions: Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal

The "LDLRAD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LDLRAD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets